肽
膀胱癌
癌症治疗
癌症
癌症研究
纳米技术
医学
材料科学
化学
内科学
生物化学
作者
Ziqi Wang,Tianrui Qu,Zhishuai Zhang,Fanshu Zeng,Hongjian Song,Kuo Zhang,Pengyu Guo,Zheming Tong,Da‐Yong Hou,Xiao Liu,Lu Wang,Hao Wang,Wanhai Xu
出处
期刊:Small
[Wiley]
日期:2024-04-25
标识
DOI:10.1002/smll.202310416
摘要
Abstract Synergistic therapy has shown greater advantages compared with monotherapy. However, the complex multiple‐administration plan and potential side effects limit its clinical application. A transformable specific‐responsive peptide ( TSRP ) is utilized to one‐step achieve synergistic therapy integrating anti‐tumor, anti‐angiogenesis and immune response. The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR‐1; ii) Transformable unit could self‐assembly and trigger nanofibers formation; iii) Reactive unit could specifically cleaved by MMP‐2/9 in tumor micro‐environment; iv) Immune unit, stimulate the release of immune cells when LTX‐315 (Immune‐associated oncolytic peptide) exposed. Once its binding to FGFR‐1, the TSRP could cleaved by MMP‐2/9 to form the nanofibers on the cell membrane, with a retention time of up to 12 h. Through suppressing the phosphorylation levels of ERK 1/2 and PI3K/AKT signaling pathways downstream of FGFR‐1, the TSRP significant inhibit the growth of tumor cells and the formation of angioginesis. Furthermore, LTX‐315 is exposed after TSRP cleavage, resulting in Calreticulin activation and CD8 + T cells infiltration. All above processes together contribute to the increasing survival rate of tumor‐bearing mice by nearly 4‐folds. This work presented a unique design for the biological application of one‐step synergistic therapy of bladder cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI